Sign in
Taking peopleNo phase

Correlation Between Visual Reading and DOlab Software Quantitative Analysis of DaT-SPECT Images

Key facts

Who runs it
Dorian Technologies S.r.l.
Where
Italy2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
120 people, planned
Started
13 Oct 2026
Expected to end
Mar 2027
Type of study
Observational
Treatments tested
  • DOlab software - DaT-SPECT workflow
  • Visual interpretation (comparator)
Record updated
17 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age 18 years or older
  • Referred for evaluation of nigrostriatal dopaminergic dysfunction to one of the participating centers between January 2015 and May 2025
  • Informed consent for data collection, or documentation that all reasonable efforts to obtain consent were made (Italian Privacy Code, art. 110)
  • 123I-ioflupane SPECT images that:
  • were acquired according to the PPMI imaging protocol
  • have a field of view covering the entire head, from the superior cortical regions to the lower cerebellum
  • followed the radiotracer manufacturer's acquisition timing and methods
  • were attenuation-corrected according to local standard procedures

Who cannot take part

  • Use of drugs or substances that may significantly affect DaT binding (e.g., cocaine, amphetamines, CNS stimulants, opioid derivatives, antidepressants, adrenergic agonists, anticholinergics, anesthetics) without a washout of at least five biological half-lives before DaT-SPECT, per the EANM/SNMMI guidelines
  • Age under 18 years
  • DaT-SPECT performed outside the January 2015 - May 2025 period
  • Images not meeting the acquisition and quality specifications listed above

This trial is currently available in Italy.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this study is to find out whether the quantitative results of DOlab software (DaT-SPECT workflow) agree with the visual reading of brain scans performed by nuclear medicine physicians. The scans are 123I-ioflupane DaT-SPECT images of adults who were evaluated for dopamine transporter dysfunction, a condition seen in Parkinson's disease, other parkinsonian syndromes and dementia with Lewy bodies.

Read full original descriptionShow less

The main questions it aims to answer are:

* Do the visual scores given by expert readers (0 = normal to 3 = marked abnormality) correlate with the values calculated by the software? * Does using the software report change or refine the readers' classification compared with visual reading alone? * How usable do readers find the software?

The study uses existing scans of 120 patients collected between January 2015 and May 2025 at two Italian hospitals. No new tests or treatments are given to participants, and the software results are not used for their clinical care.

The group in the trial

  • Adults referred for DaT-SPECT

    Adults referred for evaluation of nigrostriatal dopaminergic dysfunction at the two participating centers between January 2015 and May 2025, whose existing 123I-ioflupane DaT-SPECT scans were selected retrospectively (30 per visual grade 0-3, 15 per grade per center). Each scan is read visually by four blinded readers, analyzed by DOlab software, and then re-read with the software report.

    Treatment: DOlab software - DaT-SPECT workflow and Visual interpretation (comparator)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pre-market Clinical Investigation to Evaluate the Correlation Between Visual Interpretation and Quantitative Analysis Performed by DOlab Software - DaT-SPECT Workflow for the Identification of Neurological Disorders Related to Dopamine Transporter Dysfunction
Record updated
17 November 2026